NO331896B1 - Farmasoytisk preparat med forsinket frigivelse inneholdende 3-(3-dimetylamino-1 etyl-2-metyl-propyl)fenol - Google Patents
Farmasoytisk preparat med forsinket frigivelse inneholdende 3-(3-dimetylamino-1 etyl-2-metyl-propyl)fenol Download PDFInfo
- Publication number
- NO331896B1 NO331896B1 NO20041924A NO20041924A NO331896B1 NO 331896 B1 NO331896 B1 NO 331896B1 NO 20041924 A NO20041924 A NO 20041924A NO 20041924 A NO20041924 A NO 20041924A NO 331896 B1 NO331896 B1 NO 331896B1
- Authority
- NO
- Norway
- Prior art keywords
- weight
- dimethylamino
- ethyl
- propyl
- methyl
- Prior art date
Links
- KWTWDQCKEHXFFR-UHFFFAOYSA-N 3-[1-(dimethylamino)-2-methylpentan-3-yl]phenol Chemical compound CN(C)CC(C)C(CC)C1=CC=CC(O)=C1 KWTWDQCKEHXFFR-UHFFFAOYSA-N 0.000 title claims abstract description 45
- 230000003111 delayed effect Effects 0.000 title claims abstract description 36
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 13
- 239000011159 matrix material Substances 0.000 claims abstract description 66
- 150000003839 salts Chemical class 0.000 claims abstract description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 17
- 238000000338 in vitro Methods 0.000 claims abstract description 13
- 229920001477 hydrophilic polymer Polymers 0.000 claims abstract description 8
- 229920001600 hydrophobic polymer Polymers 0.000 claims abstract description 7
- 239000013543 active substance Substances 0.000 claims description 59
- 238000000034 method Methods 0.000 claims description 19
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 15
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 15
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 8
- 229920002678 cellulose Polymers 0.000 claims description 8
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 7
- KWTWDQCKEHXFFR-RISCZKNCSA-N 3-[(2s,3s)-1-(dimethylamino)-2-methylpentan-3-yl]phenol Chemical compound CN(C)C[C@@H](C)[C@H](CC)C1=CC=CC(O)=C1 KWTWDQCKEHXFFR-RISCZKNCSA-N 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 229920003086 cellulose ether Polymers 0.000 claims description 6
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 5
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 5
- 230000036470 plasma concentration Effects 0.000 claims description 5
- KWTWDQCKEHXFFR-SMDDNHRTSA-N tapentadol Chemical compound CN(C)C[C@H](C)[C@@H](CC)C1=CC=CC(O)=C1 KWTWDQCKEHXFFR-SMDDNHRTSA-N 0.000 claims description 5
- 238000001514 detection method Methods 0.000 claims description 4
- 210000003462 vein Anatomy 0.000 claims description 4
- 229920001249 ethyl cellulose Polymers 0.000 claims description 3
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 3
- 238000001727 in vivo Methods 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 abstract description 21
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 abstract 2
- NGFPWHGISWUQOI-UHFFFAOYSA-N 2-sec-butylphenol Chemical compound CCC(C)C1=CC=CC=C1O NGFPWHGISWUQOI-UHFFFAOYSA-N 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 69
- 239000003826 tablet Substances 0.000 description 61
- 238000009472 formulation Methods 0.000 description 28
- 239000003814 drug Substances 0.000 description 14
- 208000002193 Pain Diseases 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- 239000002775 capsule Substances 0.000 description 9
- 238000000576 coating method Methods 0.000 description 9
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 8
- 230000000202 analgesic effect Effects 0.000 description 8
- 239000011248 coating agent Substances 0.000 description 8
- 229940016286 microcrystalline cellulose Drugs 0.000 description 8
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 8
- 239000008108 microcrystalline cellulose Substances 0.000 description 8
- 239000000945 filler Substances 0.000 description 7
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 7
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- ZELFLGGRLLOERW-YECZQDJWSA-N 3-[(2r,3r)-1-(dimethylamino)-2-methylpentan-3-yl]phenol;hydrochloride Chemical compound Cl.CN(C)C[C@H](C)[C@@H](CC)C1=CC=CC(O)=C1 ZELFLGGRLLOERW-YECZQDJWSA-N 0.000 description 3
- 208000000094 Chronic Pain Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000012736 aqueous medium Substances 0.000 description 3
- 239000012876 carrier material Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 150000002191 fatty alcohols Chemical class 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- -1 hydroxypropyl Chemical group 0.000 description 3
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229960001375 lactose Drugs 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 229910002012 Aerosil® Inorganic materials 0.000 description 2
- 229920003110 Primojel Polymers 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 230000004941 influx Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000001050 lubricating effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920000193 polymethacrylate Polymers 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- AYTRQOLWFRRPKZ-UHFFFAOYSA-N 3-[1-(dimethylamino)-2-methylpentan-3-yl]phenol;lead Chemical compound [Pb].CN(C)CC(C)C(CC)C1=CC=CC(O)=C1 AYTRQOLWFRRPKZ-UHFFFAOYSA-N 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 241001440269 Cutina Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 241000275031 Nica Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000037058 blood plasma level Effects 0.000 description 1
- 238000000237 capillary viscometry Methods 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 230000008095 long lasting therapeutic effect Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000013563 matrix tablet Substances 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10152469A DE10152469A1 (de) | 2001-10-24 | 2001-10-24 | 3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol enthaltendes Arzneimittel mit verzögerter Wirkstofffreisetzung |
DE2002148309 DE10248309A1 (de) | 2002-10-16 | 2002-10-16 | 3-(3- Dimethylamino-1-ethyl-2-methyl-propyl) phenol enthaltendes Arzeimittel mit verzögerter Wirkstofffreisetzung |
PCT/EP2002/011809 WO2003035053A1 (de) | 2001-10-24 | 2002-10-22 | 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol enthaltendes arzneimittel mit verzögerter wirkstofffreisetzung |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20041924L NO20041924L (no) | 2004-05-11 |
NO331896B1 true NO331896B1 (no) | 2012-04-30 |
Family
ID=26010444
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20041924A NO331896B1 (no) | 2001-10-24 | 2004-05-11 | Farmasoytisk preparat med forsinket frigivelse inneholdende 3-(3-dimetylamino-1 etyl-2-metyl-propyl)fenol |
NO2012007C NO2012007I2 (no) | 2001-10-24 | 2012-05-08 | Tapentadol (1R,2R)-3-(3-dimetylamino-1-etyl-2-metylpropyl)fenol eller et farmasøytisk godtakbart salt derav |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO2012007C NO2012007I2 (no) | 2001-10-24 | 2012-05-08 | Tapentadol (1R,2R)-3-(3-dimetylamino-1-etyl-2-metylpropyl)fenol eller et farmasøytisk godtakbart salt derav |
Country Status (29)
Country | Link |
---|---|
US (7) | US20050058706A1 (zh) |
EP (1) | EP1439829B1 (zh) |
JP (2) | JP4758064B2 (zh) |
KR (1) | KR100958045B1 (zh) |
CN (1) | CN100402021C (zh) |
AR (1) | AR036943A1 (zh) |
AT (1) | ATE303802T1 (zh) |
AU (1) | AU2002349001C1 (zh) |
BR (1) | BRPI0213653B8 (zh) |
CA (1) | CA2464578C (zh) |
CO (1) | CO5570662A2 (zh) |
CY (1) | CY2012022I2 (zh) |
DE (1) | DE50204198D1 (zh) |
DK (1) | DK1439829T3 (zh) |
EC (1) | ECSP045102A (zh) |
ES (1) | ES2248622T3 (zh) |
HK (1) | HK1068539A1 (zh) |
HU (1) | HU230161B1 (zh) |
IL (2) | IL161587A0 (zh) |
MX (1) | MXPA04003742A (zh) |
MY (1) | MY127797A (zh) |
NO (2) | NO331896B1 (zh) |
NZ (1) | NZ532999A (zh) |
PE (1) | PE20030527A1 (zh) |
PL (1) | PL216535B1 (zh) |
PT (1) | PT1439829E (zh) |
SI (1) | SI1439829T1 (zh) |
WO (2) | WO2003035054A1 (zh) |
ZA (1) | ZA200403928B (zh) |
Families Citing this family (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
SI1685829T1 (sl) | 2002-11-22 | 2008-08-31 | Gruenenthal Gmbh | Uporaba (1RS,3RS,6RS)-6-dimetilaminometil-1- (3-metoksi-fenil)-cikloheksan-1, 3-diola za zdravljenje vnetne bolečine |
US8075872B2 (en) | 2003-08-06 | 2011-12-13 | Gruenenthal Gmbh | Abuse-proofed dosage form |
DE102004032051A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform |
ES2407143T3 (es) * | 2003-08-06 | 2013-06-11 | Grünenthal GmbH | Forma de dosificación protegida contra un posible abuso |
DE102005005446A1 (de) * | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
DE102004020220A1 (de) * | 2004-04-22 | 2005-11-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform |
DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
US20070048228A1 (en) * | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
PT1612203E (pt) * | 2004-06-28 | 2007-08-20 | Gruenenthal Gmbh | ''formas cristalinas de cloridrato de (-) - (1r,2r) - 3 -(3-dimetilamino-l-etil - 2 - metilpropil) fenol'' |
AR053304A1 (es) * | 2004-07-01 | 2007-05-02 | Gruenenthal Gmbh | Formas farmaceuticas orales protegidas frente al abuso con liberacion controlada de (1r,2r)-3-(3 dimetilamino-1-etil-2metil-propil)fenol y procedimiento para su produccion. |
DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
DE102004032103A1 (de) * | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
ATE494889T1 (de) * | 2006-04-28 | 2011-01-15 | Gruenenthal Gmbh | Pharmazeutische kombination mit 3- (3- dimethylamino-1-ethyl-2-methyl-propyl)-phenol und paracetamol |
KR101517064B1 (ko) * | 2006-04-28 | 2015-04-30 | 그뤼넨탈 게엠베하 | 3-(3-디메틸아미노-1-에틸-2-메틸-프로필)-페놀 및 nsaid를 포함하는 약제학적 병용제 |
CN101091725A (zh) * | 2006-06-23 | 2007-12-26 | 天津天士力制药股份有限公司 | 一种中药颗粒及其制备方法 |
SA07280459B1 (ar) | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني |
DE102007011485A1 (de) * | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
DE102007019417A1 (de) | 2007-04-23 | 2008-11-13 | Grünenthal GmbH | Tapentadol zur Schmerzbehandlung bei Arthrose |
EP1985292A1 (en) * | 2007-04-23 | 2008-10-29 | Grünenthal GmbH | Titration of tapentadol |
DK2596784T3 (en) * | 2007-11-23 | 2017-03-06 | Gruenenthal Gmbh | Tapentadol compositions |
SI2240431T1 (sl) * | 2007-12-07 | 2017-05-31 | Gruenenthal Gmbh | Kristalinične modifikacije (1R,2R)-3-(3-dimetilamino-1-etil-2-metil-propil)-fenola |
BRPI0906467C1 (pt) * | 2008-01-25 | 2021-05-25 | Gruenenthal Gmbh | forma de dosagem farmacêutica com formato exterior modificado resistente à ruptura e com liberação controlada |
LT2273983T (lt) | 2008-05-09 | 2016-10-25 | Grünenthal GmbH | Tarpinės miltelių kompozicijos gamybos būdas ir galutinė kieta dozavimo forma naudojant purškalo kietinimo stadija |
US20100190752A1 (en) * | 2008-09-05 | 2010-07-29 | Gruenenthal Gmbh | Pharmaceutical Combination |
CN104257600A (zh) | 2008-10-30 | 2015-01-07 | 格吕伦塔尔有限公司 | 新型有效的他喷他多剂型 |
TW201105316A (en) | 2009-07-22 | 2011-02-16 | Gruenenthal Gmbh | Hot-melt extruded pharmaceutical dosage form |
KR101747156B1 (ko) | 2009-07-22 | 2017-06-27 | 그뤼넨탈 게엠베하 | 산화-안정화된 탬퍼-내성 용량형 |
CN102821757B (zh) * | 2010-02-03 | 2016-01-20 | 格吕伦塔尔有限公司 | 通过挤出机制备粉末状药物组合物 |
JP5905872B2 (ja) * | 2010-04-07 | 2016-04-20 | ルピン・リミテッド | タペンタドールの制御放出医薬組成物 |
US20130116333A1 (en) * | 2010-05-05 | 2013-05-09 | Ratiopharm Gmbh | Solid tapentadol in non-crystalline form |
AU2011267474B2 (en) * | 2010-06-15 | 2016-05-26 | Grünenthal GmbH | Pharmaceutical combination for the treatment of pain |
ES2591354T3 (es) | 2010-06-30 | 2016-11-28 | Grünenthal GmbH | Tapentadol para su uso en el tratamiento del síndrome de intestino irritable |
MX341072B (es) | 2010-07-23 | 2016-08-05 | Grünenthal Gmbh * | Sales o co-cristales de 3-(3-dimetilamino-1-etil-2-metil-propil)-f enol. |
RU2607499C2 (ru) | 2010-09-02 | 2017-01-10 | Грюненталь Гмбх | Устойчивая к разрушению лекарственная форма, которая содержит анионный полимер |
MX2013002377A (es) | 2010-09-02 | 2013-04-29 | Gruenenthal Gmbh | Forma de dosificacion resistente a manipulacion que comprende una sal inorganica. |
DK2680833T3 (en) | 2011-03-04 | 2016-05-23 | Gruenenthal Gmbh | PARENTERAL SUBMISSION OF TAPENTADOL |
CN103501773A (zh) | 2011-03-04 | 2014-01-08 | 格吕伦塔尔有限公司 | 用于口服给予的他喷他多含水药物制剂 |
PT2680834T (pt) | 2011-03-04 | 2018-01-25 | Gruenenthal Gmbh | Composição farmacêutica aquosa semissólida contendo tapentadol |
WO2012136351A1 (en) | 2011-04-05 | 2012-10-11 | Grünenthal GmbH | Tapentadol for treating pain associated with trigeminal neuralgia |
JP2014510759A (ja) | 2011-04-05 | 2014-05-01 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 疼痛の慢性化を予防するためのタペンタドール |
ES2788548T3 (es) | 2011-04-29 | 2020-10-21 | Gruenenthal Gmbh | Tapentadol para la prevención y el tratamiento de la depresión y la ansiedad |
SI2736501T1 (en) | 2011-07-29 | 2018-03-30 | Gruenenthal Gmbh | Intrathecal or epidural administration of 3 - ((1S, 2S) -3- (dimethylamino) -1-ethyl-2-methylpropyl) phenol |
EA201400172A1 (ru) | 2011-07-29 | 2014-06-30 | Грюненталь Гмбх | Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства |
EA201400173A1 (ru) | 2011-07-29 | 2014-06-30 | Грюненталь Гмбх | Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства |
EP2606879A1 (en) | 2011-12-21 | 2013-06-26 | Hexal AG | Multiple unit pellet tablet formulation comprising an opioid |
JP6117249B2 (ja) | 2012-02-28 | 2017-04-19 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 薬理学的に活性な化合物および陰イオン性ポリマーを含むタンパーレジスタント剤形 |
JP6282261B2 (ja) | 2012-04-18 | 2018-02-21 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 不正使用防止および過量放出防止医薬剤形 |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
AR096439A1 (es) | 2013-05-29 | 2015-12-30 | Gruenenthal Gmbh | Forma de dosificación resistente al uso indebido que contiene una o más partículas |
AU2014273227B2 (en) | 2013-05-29 | 2019-08-15 | Grunenthal Gmbh | Tamper-resistant dosage form containing one or more particles |
EP2808319A1 (en) | 2013-05-31 | 2014-12-03 | Arevipharma GmbH | 3-[3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex |
CA2917136C (en) | 2013-07-12 | 2022-05-31 | Grunenthal Gmbh | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
EP2845625A1 (en) | 2013-09-04 | 2015-03-11 | Grünenthal GmbH | Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome |
WO2015071248A1 (en) | 2013-11-15 | 2015-05-21 | Synthon B.V. | Abuse-proofed extended release pharmaceutical composition comprising tapentadol |
JP6480936B2 (ja) | 2013-11-26 | 2019-03-13 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | クライオミリングによる粉末状医薬組成物の調製 |
EP2942054A1 (en) * | 2014-05-09 | 2015-11-11 | G.L. Pharma GmbH | Slow-release pharmaceutical formulation |
AU2015261060A1 (en) | 2014-05-12 | 2016-11-03 | Grunenthal Gmbh | Tamper resistant immediate release capsule formulation comprising Tapentadol |
EA201692388A1 (ru) | 2014-05-26 | 2017-05-31 | Грюненталь Гмбх | Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы |
SI3273953T1 (sl) | 2015-03-27 | 2019-03-29 | Gruenenthal Gmbh | Stabilna oblika za parenteralno dovajanje tapentadola |
MX2017013637A (es) | 2015-04-24 | 2018-03-08 | Gruenenthal Gmbh | Forma de dosificacion resistente a alteraciones con liberacion inmediata y resistencia contra la extraccion por solventes. |
CA2998259A1 (en) | 2015-09-10 | 2017-03-16 | Grunenthal Gmbh | Protecting oral overdose with abuse deterrent immediate release formulations |
EP3231420A1 (en) | 2016-02-29 | 2017-10-18 | G.L. Pharma GmbH | Abuse-deterrent pharmaceutical compositions |
EA201990744A1 (ru) | 2016-09-23 | 2019-08-30 | Грюненталь Гмбх | Стабильная лекарственная форма для парентерального введения тапентадола |
WO2018153947A1 (en) | 2017-02-23 | 2018-08-30 | Grünenthal GmbH | Tapentadol as local anesthetic |
WO2018219897A1 (en) * | 2017-05-29 | 2018-12-06 | Grünenthal GmbH | Multiparticulate oral dosage form providing prolonged release of tapentadol |
WO2021175773A1 (en) | 2020-03-02 | 2021-09-10 | Grünenthal GmbH | Dosage form providing prolonged release of tapentadol phosphoric acid salt |
AU2020100442B4 (en) * | 2020-03-02 | 2020-06-18 | Grünenthal GmbH | Dosage form providing prolonged release of tapentadol phosphoric acid salt |
EP3875079A1 (en) | 2020-03-02 | 2021-09-08 | Grünenthal GmbH | Dosage form providing prolonged release of tapentadol phosphoric acid salt |
HRP20240081T1 (hr) * | 2020-03-02 | 2024-05-24 | Grünenthal GmbH | Oblik doziranja koji pruža produljeno oslobađanje soli tapentadol-fosforne kiseline |
AU2020100441B4 (en) * | 2020-03-02 | 2020-06-18 | Grünenthal GmbH | Dosage form providing prolonged release of tapentadol phosphoric acid salt |
AU2021237693A1 (en) | 2020-03-16 | 2022-09-08 | Grünenthal GmbH | Scored tablet |
DE202020104285U1 (de) | 2020-07-24 | 2020-12-18 | Grünenthal GmbH | Ethylcellulose-beschichtete Partikel enthaltend ein Salz aus Tapentadol und Phosphorsäure |
DE202020005470U1 (de) | 2020-11-10 | 2022-01-25 | Grünenthal GmbH | Darreichungsformen mit verlängerter Freisetzung eines Salzes von Tapentadol mit L-(+)-Weinsäure |
WO2022101247A1 (de) | 2020-11-10 | 2022-05-19 | Grünenthal GmbH | Darreichungsformen mit verlängerter freisetzung eines salzes von tapentadol mit l-(+)-weinsäure |
DK3995135T3 (da) * | 2020-11-10 | 2022-08-22 | Gruenenthal Gmbh | Doseringsform med forlænget afgivelse af et salt af tapentadol med l-(+)-vinsyre |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3870790A (en) * | 1970-01-22 | 1975-03-11 | Forest Laboratories | Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose |
DE2117239A1 (de) | 1971-04-08 | 1972-11-16 | König, Wilhelm, 4712 Werne | Verfahren zum Erstellen von Wänden aus Schalungssteinen |
US4126672A (en) * | 1976-02-04 | 1978-11-21 | Hoffmann-La Roche Inc. | Sustained release pharmaceutical capsules |
US4389393A (en) | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
US4443428A (en) * | 1982-06-21 | 1984-04-17 | Euroceltique, S.A. | Extended action controlled release compositions |
US5688645A (en) | 1983-01-10 | 1997-11-18 | Gen-Probe Incorporated | Method for detecting, identifying, and quantitating non-viral organisms |
US4612008A (en) * | 1983-05-11 | 1986-09-16 | Alza Corporation | Osmotic device with dual thermodynamic activity |
US4783337A (en) * | 1983-05-11 | 1988-11-08 | Alza Corporation | Osmotic system comprising plurality of members for dispensing drug |
US4765989A (en) * | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
GB8519310D0 (en) | 1985-07-31 | 1985-09-04 | Zyma Sa | Granular active substances |
GB8626098D0 (en) * | 1986-10-31 | 1986-12-03 | Euro Celtique Sa | Controlled release hydromorphone composition |
US5126145A (en) * | 1989-04-13 | 1992-06-30 | Upsher Smith Laboratories Inc | Controlled release tablet containing water soluble medicament |
US5266331A (en) * | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
US5478577A (en) * | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
US5286493A (en) * | 1992-01-27 | 1994-02-15 | Euroceltique, S.A. | Stabilized controlled release formulations having acrylic polymer coating |
RU2121830C1 (ru) * | 1992-09-18 | 1998-11-20 | Яманоути Фармасьютикал Ко., ЛТД | Гидрогелевый препарат с длительным высвобождением лекарства |
IL109460A (en) * | 1993-05-10 | 1998-03-10 | Euro Celtique Sa | Controlled release formulation comprising tramadol |
IL110014A (en) * | 1993-07-01 | 1999-11-30 | Euro Celtique Sa | Solid controlled-release oral dosage forms of opioid analgesics |
DE4329794C2 (de) | 1993-09-03 | 1997-09-18 | Gruenenthal Gmbh | Tramadolsalz enthaltende Arzneimittel mit verzögerter Wirkstofffreisetzung |
SG44669A1 (en) | 1993-11-17 | 1997-12-19 | Traditional Cn Med Res Lab Inc | Compositions for curing affected abnormal tissues method for the preparation thereof and usage thereof |
US5891471A (en) * | 1993-11-23 | 1999-04-06 | Euro-Celtique, S.A. | Pharmaceutical multiparticulates |
US5843480A (en) * | 1994-03-14 | 1998-12-01 | Euro-Celtique, S.A. | Controlled release diamorphine formulation |
DE4426245A1 (de) | 1994-07-23 | 1996-02-22 | Gruenenthal Gmbh | 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung |
US5478572A (en) * | 1994-09-06 | 1995-12-26 | Bristol-Myers Squibb Co. | Gepirone dosage form |
CN1125572A (zh) * | 1994-12-28 | 1996-07-03 | 顺德市广容制药厂 | 一种罗通定痛释片的制作方法 |
IL139728A (en) * | 1995-01-09 | 2003-06-24 | Penwest Pharmaceuticals Compan | Aqueous slurry composition containing microcrystalline cellulose for preparing a pharmaceutical excipient |
DE19525137C2 (de) | 1995-07-11 | 2003-02-27 | Gruenenthal Gmbh | 6-Dimethylaminomethyl-1-phenyl-cyclohexanverbin -dungen als Zwischenprodukte zur Herstellung pharmazeutischer Wirkstoffe |
DE19609847A1 (de) | 1996-03-13 | 1997-09-18 | Gruenenthal Gmbh | Dimethyl-(3-aryl-but-3-enyl)-aminverbindungen als pharmazeutische Wirkstoffe |
US6096339A (en) | 1997-04-04 | 2000-08-01 | Alza Corporation | Dosage form, process of making and using same |
ES2322405T3 (es) * | 1996-07-08 | 2009-06-19 | Penwest Pharmaceuticals Co. | Matriz de liberacion controlada para farmacos insolubles en dosis elevadas. |
DE19630035A1 (de) | 1996-07-25 | 1998-01-29 | Asta Medica Ag | Tramadol Multiple Unit Formulierungen |
AU729529B2 (en) * | 1997-06-06 | 2001-02-01 | Depomed, Inc. | Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs |
US6245357B1 (en) * | 1998-03-06 | 2001-06-12 | Alza Corporation | Extended release dosage form |
US6106862A (en) * | 1998-08-13 | 2000-08-22 | Andrx Corporation | Once daily analgesic tablet |
DE19901683B4 (de) | 1999-01-18 | 2005-07-21 | Grünenthal GmbH | Analgetikum mit kontrollierter Wirkstofffreisetzung |
BRPI0015284B8 (pt) * | 1999-10-29 | 2021-05-25 | Euro Celtique S/A | formulações de hidrocodona de liberação controlada |
DE10109763A1 (de) | 2001-02-28 | 2002-09-05 | Gruenenthal Gmbh | Pharmazeutische Salze |
DE10248309A1 (de) | 2002-10-16 | 2004-04-29 | Grünenthal GmbH | 3-(3- Dimethylamino-1-ethyl-2-methyl-propyl) phenol enthaltendes Arzeimittel mit verzögerter Wirkstofffreisetzung |
-
2002
- 2002-10-18 PE PE2002001030A patent/PE20030527A1/es active IP Right Grant
- 2002-10-22 PT PT02781278T patent/PT1439829E/pt unknown
- 2002-10-22 JP JP2003537620A patent/JP4758064B2/ja not_active Expired - Lifetime
- 2002-10-22 DK DK02781278T patent/DK1439829T3/da active
- 2002-10-22 CN CNB028259769A patent/CN100402021C/zh not_active Expired - Lifetime
- 2002-10-22 PL PL369756A patent/PL216535B1/pl unknown
- 2002-10-22 KR KR1020047006113A patent/KR100958045B1/ko active Protection Beyond IP Right Term
- 2002-10-22 EP EP02781278A patent/EP1439829B1/de not_active Expired - Lifetime
- 2002-10-22 IL IL16158702A patent/IL161587A0/xx unknown
- 2002-10-22 SI SI200230224T patent/SI1439829T1/sl unknown
- 2002-10-22 AT AT02781278T patent/ATE303802T1/de active
- 2002-10-22 WO PCT/EP2002/011806 patent/WO2003035054A1/de not_active Application Discontinuation
- 2002-10-22 DE DE50204198T patent/DE50204198D1/de not_active Expired - Lifetime
- 2002-10-22 NZ NZ532999A patent/NZ532999A/en not_active IP Right Cessation
- 2002-10-22 CA CA2464578A patent/CA2464578C/en not_active Expired - Lifetime
- 2002-10-22 AU AU2002349001A patent/AU2002349001C1/en active Active
- 2002-10-22 MX MXPA04003742A patent/MXPA04003742A/es active IP Right Grant
- 2002-10-22 HU HU0402104A patent/HU230161B1/hu unknown
- 2002-10-22 BR BRPI0213653A patent/BRPI0213653B8/pt active IP Right Grant
- 2002-10-22 ES ES02781278T patent/ES2248622T3/es not_active Expired - Lifetime
- 2002-10-22 WO PCT/EP2002/011809 patent/WO2003035053A1/de active IP Right Grant
- 2002-10-23 AR ARP020104010A patent/AR036943A1/es not_active Application Discontinuation
- 2002-10-24 MY MYPI20023979A patent/MY127797A/en unknown
-
2004
- 2004-04-22 CO CO04037005A patent/CO5570662A2/es not_active Application Discontinuation
- 2004-04-22 IL IL161587A patent/IL161587A/en active IP Right Grant
- 2004-04-26 US US10/831,368 patent/US20050058706A1/en not_active Abandoned
- 2004-05-11 NO NO20041924A patent/NO331896B1/no not_active IP Right Cessation
- 2004-05-12 EC EC2004005102A patent/ECSP045102A/es unknown
- 2004-05-20 ZA ZA2004/03928A patent/ZA200403928B/en unknown
-
2005
- 2005-01-27 HK HK05100703A patent/HK1068539A1/xx not_active IP Right Cessation
-
2010
- 2010-08-05 JP JP2010176084A patent/JP2010280697A/ja active Pending
-
2011
- 2011-09-23 US US13/242,800 patent/US20120034304A1/en not_active Abandoned
-
2012
- 2012-05-08 NO NO2012007C patent/NO2012007I2/no unknown
- 2012-08-13 CY CY2012022C patent/CY2012022I2/el unknown
-
2013
- 2013-04-23 US US13/868,635 patent/US20130237608A1/en not_active Abandoned
-
2016
- 2016-02-08 US US15/018,529 patent/US20160151309A1/en not_active Abandoned
- 2016-12-13 US US15/377,628 patent/US20170087103A1/en not_active Abandoned
-
2018
- 2018-04-02 US US15/943,175 patent/US20180221308A1/en not_active Abandoned
-
2019
- 2019-10-14 US US16/600,974 patent/US11007156B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11007156B2 (en) | Prolonged release pharmaceutical composition containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol | |
US10335379B2 (en) | Oral dosage forms of ketamine | |
US20100196473A1 (en) | Pharmaceutical Composition Containing 6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol with Delayed Active Ingredient Release | |
RU2325163C2 (ru) | Композиции с пролонгированным высвобождением, включающие ламотригин | |
CZ214094A3 (en) | Medicaments containing tremadol salt with protracted release of active component | |
JP2013501810A (ja) | 医薬組成物 | |
WO2011039686A1 (en) | Latrepirdine oral sustained release dosage forms | |
WO2017062997A1 (en) | Pharmaceutical formulation | |
AU2006291422B2 (en) | 3-(2-dimethylaminomethyl cyclohexyl) phenol retard formulation | |
JP2003267889A (ja) | 持続性医薬製剤 | |
EP2010158B1 (en) | Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix | |
US7410965B2 (en) | Delayed release pharmaceutical composition containing 1-dimethyl-amino-3-(3-methoxyphenyl)-2-methyl-pentan-3-ol | |
CA2739611C (en) | Pharmaceutical containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol and providing delayed release of the active ingredient | |
CA2488220C (en) | Medicament with delayed active constituent release containing 1-dimethylamino-3-(3-methoxyphenyl)-2-methylpentan-3-ol | |
JP2011140510A (ja) | 塩酸ブプロピオンの放出調節錠剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
SPCF | Filing of supplementary protection certificate |
Free format text: PRODUCT NAME: PALEXIA; NAT. REG. NO/DATE: 09-6802-6810 20110107; FIRST REG. NO/DATE: DE , 75043-48.00.00 20100819 Spc suppl protection certif: 2012007 Filing date: 20120508 |
|
SPCG | Granted supplementary protection certificate |
Free format text: PRODUCT NAME: PALEXIA; NAT. REG. NO/DATE: 09-6802-6810 20110107; FIRST REG. NO/DATE: DE , 75043-48.00.00 20100819 Spc suppl protection certif: 2012007 Filing date: 20120508 Extension date: 20250819 |
|
MK1K | Patent expired |